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Abbreviations  
3APS  3-amino-1-propeosulfonic acid 
AD  Alzheimer's disease 
Aldh1L1  aldehyde dehydrogenase 1 family member L1 
APO E  apolipoprotein E 
APP  amyloid precursor protein 
Aβ  amyloid beta 
AβPP  amyloid precursor protein 
Best 1  bestrophin 1 
CI’s  cholesterinase inhibitor's 
CNS  central nervous system 
DG  dentate gyrus 
EC  entorhinal cortex 
ECE-2  endothelin-converting enzyme-2 
EEG  electroencephalogram 
FA  formaldehyde 
FAD  familiar Alzheimer's disease 
GABA-T  gamma aminobutyric acid transaminase 
GAD 67  glutamic acid decarboxylase 
GAT3/4  GABA transporter protein 
GFAP  glial fibrilliary acidic protein 
GLT1  glutamate transporter 1 
GS  glutamine synthetase 
hAPP  human amyloid precursor protein 
LOAD  "late-onset"- Alzheimer's disease 
Maob  monoamine oxidase b 
mIPSCs  miniature inhibitory postsynaptic currents 
NDS  normal donkey serum 
NFTs  neurofibrilliary tangles 
NMDA  N-methyl-D-aspartate 
OB  olfactory bulb 
PBS  phosphate buffered saline 
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PGE2  prostaglandin-2 
PICALM  Astrocytic Regulation of Glutamate 
PSEN1  presenelin 1 
ROI  region of interest 
S100β  S100 calcium-binding protein B 
TNFα  tumor necrosis factor-α 
WT  wild type 
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1. Introduction  
 
1.1  Alzheimer’s Disease 
 
With more than 35 million patients worldwide, Alzheimer’s disease (AD) is the 
most common cause of dementia today [1]. At a meeting in Tübingen, Germany, 
the German psychiatrist Dr. Alois Alzheimer first described neuropathological 
characteristics of the disease, like neuritic plaques and neurofibrillary tangles 
(NFTs) in the post mortem brain of a 55-year-old patient.  The patient had 
suffered from severe memory loss and hallucinations [2]. Over the course of the 
century, it became clear that excessive neuronal loss is accompanied by 
destruction of functional synapses and perturbations in the excitatory and 
inhibitory neuronal activity in the AD brain [3, 4].  
The NFTs described by Dr. Alzheimer are known to cause neuronal network 
dysfunction and clinical progression of AD and are built up by the microtubule 
stabilizing protein tau, which is hyperphosphorylated in AD [5, 6].  
Amyloid plaques, which are also known to be a pathological hallmark of AD, are 
deposits of another protein, amyloid beta (Aβ). Aβ is a by-product of the amyloid 
precursor protein (APP) processing and arises from the cleavage of the 
transmembrane protein by β- and γ- secretases [6]. 
First, β-secretase cleaves the protein at its extracellular domain (β-secretase 
cleavage), generating β-C-terminal fragments. These fragments are 
subsequently cleaved by γ-secretase in the transmembrane part of AβPP, 
resulting in the release of Aβ protein [7]. γ-secretase is able to cut AβPP at 
multiple sites, producing Aβ proteins of different lengths; i.e. Aβ38, Aβ40 and 
Aβ42. Aβ42 is the most toxic version and is known to aggregate and to develop 
amyloid plaques [5, 7-9]. It has been reported that the most pathogenic version 
of Aβ are soluble oligomeric forms [8]. Also, one of the characteristics of AD, the 
loss of synapses in the hippocampus and cortex, is considered to be caused by 
oligomeric Aβ [8].    
More than 90% of all AD cases develop clinical symptoms after the age of 65 
years. They are often referred to as “sporadic” or “late-onset” AD (LOAD). Genetic 
factors, like apolipoprotein E4 (APO E4) and Phosphatidylinositol Binding 
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Clathrin Assembly Protein (PICALM) are further risk factors for developing LOAD 
[5, 10].  
A small percentage (<10%) of all AD cases is hereditary. This form of the disease 
is called familiar Alzheimer’s disease (FAD) and is mainly attributed to mutations 
in genes encoding amyloid precursor protein (APP), presenilin 1 (PS1) and 
presenilin 2 (PS2) [5]. While mutations in APP are responsible for overproduction 
of APP and Aβ [1], mutations in PSEN1 and PSEN2, which are part of the γ-
secretase complex, are the cause for an increased Aβ42 cleavage from APP [11].   
Several types of therapies exist for the various expressions of the disease, which, 
however, do not stop the disease but rather slow its progression. 
Cholesterinase inhibitors (CIs) can be used as a first line treatment for mild to 
moderate forms of the disease and are supposed to prevent memory loss and 
decline of other cognitive and non-cognitive functions. It’s believed that 
cholinergic systems in the basal forebrain are impaired early during disease 
progression, leading to loss of acetylcholinergic neurons and decreased 
production of acetylcholine [12].  
Moderate to severe forms of AD can be treated with memantine, a non-
competitive, moderate-affinity N-methyl-D-aspartate (NMDA) agonist which 
prevents excitotoxicity in neurons [12].  
There is also a so-called disease-modifying approach for AD treatment, targeting 
the development, increase or elimination of toxic aggregates or misfolded forms 
of Aβ and tau. Examples are the synthetic glycosaminoglycan 3-amino-1-
propeosulfonic acid (3APS) tramiprosate, which is supposed to hinder the binding 
of glycosaminoglycanes and Aβ, or β-secretase inhibitors like methylene blue 
[12]. Behavioral symptoms of the disease can be treated by the use of an 
antipsychotic and an antidepressant at the same time [12]. 
All of these treatments are only symptomatic, trying to counterbalance the 
neuronal disturbance, and to date no cure for AD is known. Therefore, it’s 
necessary to understand the mechanisms underlying the origin and the 
progression of the disease in its complexity, so that improved treatment options 
can be developed in the future.  
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1.2  Astrocytes  
 
Astrocytes are glial cells and part of the central nervous system (CNS). They were 
named astrocytes by Michael von Lenhossek in 1895 due to their numerous 
processes, which give them a star-shaped cell structure. This morphology also 
allows to differentiate them from other glial cells like microglia and oligodendroglia 
[6].  
Later, astrocytes were subdivided into fibrous and protoplasmic forms. 
Protoplasmic astrocytes are located in the gray matter and interact with neurons 
at pre- and postsynaptic elements, while fibrous astrocytes are located in the 
white matter and interact with myelinated axons [6, 13]. 
With the emergence of the extracellular matrix receptor CD44 as an astrocytic 
marker, several other astrocytic subpopulations have been found, such as a 
mixed protoplasmic and fibrous phenotype with long processes [6]. 
While it was originally thought that astrocytes were non-excitable cells that were 
mere „brain glue“ and had only supporting function [14], this view has changed 
over the past decades. Astrocytes are key for almost every vital CNS function, 
including neurogenesis, synapse development and function, regulation of blood 
flow, energy metabolism, ion and water homeostasis, proper function of the blood 
brain barrier and neurotransmission [13].  
In addition, astrocytes play an important role in preventing glutamate-induced 
excitotoxicity, as they can take up glutamate from the synaptic cleft via amino 
acid transporters like glutamate transporter 1 (GLT1). Subsequently, glutamate 
is metabolized into glutamine by glutamine synthetase and transferred to the 
presynaptic neuron [15]. 
Astrocytes also possess enzymes like glutamic acid decarboxylase (GAD 67) and 
gamma aminobutyric acid transaminase (GABA-T), which allow them to 
synthesize and metabolize GABA. The ability to also release the neurotransmitter 
via bestrophin 1 (Best 1) channels show that they also play an important role in 
maintaining GABA levels [15, 16].  
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In summary, astrocytes play an important role in regulating brain homeostasis 
and activity, and disease-related impairment of their abilities or malfunction can 
lead to or aggravate brain pathologies.  
 
1.3  Astrocytes can become reactive in AD  
 
As previously mentioned, under physiological conditions astrocytes have a star-
like appearance, whereas under pathological conditions, like brain injury, stroke 
or AD, astrocytes can become reactive.  
There are several markers for a reactive astrocytes, including cell hypertrophy, 
increased intracellular concentration of glial fibrillary acidic protein (GFAP) and 
S100 calcium-binding protein β (S100β) as well as expression and release of 
inflammatory mediators [6, 17]. In AD, these changes are caused by Aβ toxicity, 
which causes activation of the astrocytes assembling in the vicinity of amyloid 
plaques [18].  
In addition, activated microglia, representing the first line of defense under 
conditions of brain damage, release cytokines like tumor necrosis factor-α 
(TNFα), interleukin-1 and prostaglandin-2 (PGE2) that can also lead to astrocyte 
reactivity [17].  
Reactive astrocytes try to shield the surrounding neuropil from amyloid plaques  
using their processes, and postmortem neuropathological studies have found an 
excessive number of reactive astrocytes were found in the vicinity of amyloid 
plaques not depending on plaque size [6]. In addition, it has been proven that 
endothelin-converting enzyme-2 (ECE-2), an enzyme that is able to degrade Aβ, 
is upregulated in astrocytes in AD, which implies that astrocytes also play a role 
in limiting the growth of amyloid plaques [19].  
As reported by Jo et al. (2014) and Wu et al. (2014), GABA content of reactive 
astrocytes in the dentate gyrus (DG) of the hippocampus is higher in amyloid-
depositing mice compared to WT mice of the same age [16, 20]. Functionally, this 
accumulation induces increased tonic inhibition of the DG network via abnormal 
GABA release by astrocytes, which ultimately results in memory deficits [16, 20]. 
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While both studies described similar results, they described different mechanisms 
underlying the effects observed.  
One difference is the choice of AD mouse models and the different age of 
experimental animals under study. Wu et al. used 5xFAD mice and found an 
increase in GABA accumulation and release from astrocytes at 6-8 months, while 
Jo et al. observed increased astrocytic GABA content and release in 8-13 months 
old APPswe/PSEN1dE9 mice.   
Of note, only Jo et al. report a positive correlation between astrocytic GABA 
content and the distance to amyloid depositions, with astrocytes further than 80 
µm away showing GABA content similar to astrocytes in control mice. Wu et al. 
describe no such correlation.  
The most important difference, however, refers to mechanisms of GABA 
accumulation in and release from astrocytes.  
Jo et al. (2014) argued that the elevated GABA levels are caused by an increased 
GABA production via monoamine oxidase b (Maob) and that GABA is 
subsequently released via Best 1 channels [20]. Wu et al. (2014) proved that 
GABA is released via GABA transporter protein (GAT3/4) and assumed that since 
expression of GAD67 was increased in reactive astrocytes in AD mice compared 
to WT mice, GAD67 may be one of the reasons for GABA accumulation in 
astrocytes [16].  
As mentioned above, both groups studied astrocytes in the DG of the 
hippocampus. So far, it is unknown if increased GABA content can also be found 
in reactive astrocytes in other brain regions. An object of interest would be the 
frontal cortex, an area that is also affected by Aβ pathology and is important for 
learning, memory and other cognitive processes [18, 21, 22].  
Moreover, it remains unknown whether astrocytic GABA accumulation solely 
represents an early biomarker of pathology or, in contrary, the astrocytic GABA 
content increases with the progression of the disease. 
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1.4  Astrocytic influence on neuronal network in aging and AD 
 
As mentioned above, astrocytes are able to release neurotransmitters like 
glutamate and GABA. The release of these neurotransmitters is correlated with 
an increased intracellular calcium concentration in astrocytes and can trigger 
small inward or outward currents in surrounding neurons [17, 18, 23]. Therefore, 
it’s likely that neurotransmitters released by astrocytes play an important role in 
maintaining physiological levels of neuronal network activity.  
In a study by Banuelos et al. (2014), it was suggested that age-dependent 
working memory impairment is linked to disturbances in cortical GABA release 
by astrocytes [24]. The authors investigated WT rats at 6 months and 22 months 
of age and found that the expression of the GABA synthetizing enzyme GAD 67 
was severely increased. GAD 67 is a catalyst for the conversion of glutamate to 
GABA in both neurons and astrocytes. Also, a decrease in the GABAB receptor 
subunits, which restrict GABA release from interneurons, and a reduced 
expression of the GABA transporter protein (GAT3/4), which removes GABA from 
the synaptic cleft and transports it back to the presynaptic terminal, was found 
[24]. This leads to the assumption that an increase in GABA synthesis and 
prolongation of GABA at the synaptic cleft may be responsible for working 
memory deficits in the prefrontal cortex of aged rats. Furthermore, this can be 
viewed as a hint that astrocytic neurotransmitter release plays a role in regulating 
neuronal networks since GAD67 is present and upregulated in astrocytes. 
Mitew et al. (2013) report that GAD67 was more active in APP/PS1 transgenic 
AD mice than in age-matched WT mice. However, this was only found in cortical 
astrocytes in AD mice acquired from purified glial synaptosome extracts.  
Since astrocytes express GAD67 and increased GAD67 activity was seen in glial 
tissue extracts, these data may serve as a further indication for the important role 
astrocytes play in maintaining neuronal network activity [25]. 
Furthermore, astrocytes are able to activate neighboring neurons by upregulation 
of glutamatergic transmission and the release of TNF-α [26, 27]. 
To sum it all up, astrocytes have widespread influences on maintaining functional 
neuronal networks. This influence seems to be altered during the aging process. 
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1.5  Network dysfunction in AD 
 
A growing number of studies report neural network hyperactivity in both humans 
and mouse models of AD. As reported by Palop et al. (2009), in patients aberrant 
cortical network activity can be seen in both the sporadic and inherited form of 
the disease [4].   
Non-convulsive epileptic-like seizures, which may be a cause of clinical 
symptoms of AD like disorientation and amnesia, have been observed during 
electroencephalogram (EEG) recordings in the hAPPJ20 mouse model of FAD. 
As a compensation for this activity, inhibitory circuits were remodeled in the 
hippocampus [28]. Furthermore, an increase in neuropeptide-Y levels as well as 
enlarged GABAergic miniature inhibitory postsynaptic currents (mIPSCs) were 
found in the DG [28].  
Busche et al. (2008) found a difference in the percentage of hyperactive and 
hypoactive neurons in a mouse model of AD compared to wild type (WT) mice at 
the same age. At 6-10 months of age, they found higher fractions of both 
hyperactive and hypoactive cortical neurons in AD mice compared to age-
matched control mice [22]. Also, AD mice performed worse than control mice in 
memory tests. At that time, this finding contradicted the accepted belief that 
neuronal network activity is decreased in AD brain. 
Additionally, the authors found a connection between hyperactive neurons and 
amyloid plaques. While hyperactive neurons were only found within a radius of 
60 µm of the nearest plaque, hypoactive neurons were found throughout the 
parenchyma [22]. The activity of hyperactive neurons was decreased by the 
application of diazepam, a benzodiazepine that increases the open probability of 
GABAA receptors [22]. 
Network dysfunction during amyloidosis has also been found in the hippocampus. 
Busche et al. (2012) revealed that in the hippocampus of 2-month-old, the 
percentage of hyperactive neurons is 24% higher in AD mice than in age matched 
WT mice [29]. The number of hyperactive neurons then decreased by 16.4% in 
AD from 1-2 months old mice to 6-7 old mice yet continued to be 6.6% higher 
than in age matched control mice. The percentage of hypoactive neurons was 
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also higher in AD mice at 6-7 months of age compared to control mice [29]. 
However, in this case the increase in neuronal network activity was not caused 
by amyloid plaques, since at this young age no plaques have developed in the 
hippocampus yet. The authors found that the presence of soluble Aβ was the 
reason for hyperactivity of neurons and proved that administration of a γ-
secretase inhibitor subsequently leads to a decrease in soluble Aβ levels and 
normalized neuronal activity. Consistently, administration of soluble Aβ lead to 
neuronal hyperactivity in WT mice [29].  
Another part of the mouse brain where similar results have been found is the 
visual cortex. A study by Grienberger et al. (2012) observed an increase in 
hyperactive and hypoactive neurons in the visual cortex of AD mice, as well as 
an impaired performance in a visual discrimination test.  
Hyperactive neurons were impaired in their tuning properties, as suggested by 
reduced orientation and direction selectivity to visual stimuli [30].  
Neurons in the visual cortex returned to normal tuning after application of the 
GABAA receptor agonist Gabazine [30]. 
Recent studies reported neuronal hyperactivity also in mutant mice without 
amyloid plaques or neuroinflammation, like mice carrying solely the PS1G384A 
mutation (hereafter referred to as “PS45” mice) [31, 32]. Furthermore, Lerdkrai et 
al. (2018) not only showed that neuronal hyperactivity can occur in the absence 
of amyloid plaques, but also during the aging process in WT mice [32].  
Asavapanumas et al. (2018) also observed neuronal hyperactivity in the visual 
cortex of AD and PS45 mice [33]. They labeled all recorded neurons as either 
silent, normal or hyperactive and found impairments in orientation and direction 
selective tuning not only in hyperactive neurons, as reported by Grienberger et 
al. (2012), but also in normal neurons in 10-12 months old AD and PS45 mice 
[33]. 
Taken together, besides the well-known morphological reactivity of astrocytes in 
the course of AD, there is also a profound disturbance of neuronal networks. Both 
of these pathological events occur in the close vicinity of amyloid plaques. 
However, if they are initiated by the same factors and how these alterations 
develop in the course of amyloidosis remains to be determined. 
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1.6  Astrocytic markers 
 
There are several markers for astrocytes, with the most established ones being 
GFAP, S100β and Glutamine Synthetase (GS). To date, no astrocytic marker 
exists that is able to reflect the full heterogeneity of astrocytes. Recently, a new 
alternative, Aldehyde dehydrogenase 1 family member L1 (Aldh1L1), was 
developed that may in the future allow to distinguish between the various 
astrocytic forms [34]. 
 
1.6.1 GFAP 
 
Since its discovery in 1969, GFAP has become one of the most reliable markers 
for astrocytes in the brain [35], However, it works well in many but not all regions 
of the brain and is mostly labelling astrocytic processes [34]. GFAP is found in 
aged as well as in juvenile astrocytes and is known to be elevated in damaged or 
degenerated brains [36].   
 
1.6.2 S100β 
 
The Ca2+ binding protein S100 has multiple paracrine trophic effects in the CNS 
and can also be used to specifically label astrocytes using immunohistochemistry 
[37].  We chose an anti-S100β antibody for our study because it produced an 
adequate staining of astrocytic cell body and processes. However, S100β also 
labels other glial cells, for example a subpopulation of oligodendrocytes [38]. 
 
1.6.3 GS 
 
GS is responsible for nitrogen metabolism and most importantly metabolism of 
the amino acid neurotransmitters glutamic acid and γ-aminobutyric acid. It has 
been shown that GS is exclusively expressed in astrocytes [39]. 
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1.6.4 ALDH1L1 
 
Aldh1L1 is an enzyme that metabolizes 10-formyltetrahydrofolate to 
tetrahydrofolate and plays an important role in de novo nucleotide biosynthesis, 
cell division and growth. Adh1L1 is present in almost all astrocytes, but no other 
CNS cells, which qualifies it as a superior marker to distinguish astrocytes from 
other glial cell types [34].  
 
 
1.7  Mouse models of AD  
 
There are numerous transgenic mouse models that express pathological features 
of AD, like cognitive and behavioral deficits, plaque formation and NFTs. 
However, a mouse model that shows all characteristics associated with AD does 
not exist yet as symptoms differ in degree and combinations [1]. For our study, 
we used the following two mouse models. 
 
1.7.1 APP23xPS45 double transgenic mice 
 
APP23xPS45 is a double transgenic mouse line generated by crossing APP23 
mice, carrying the Human App Swedish (670/671) mutation [40] with PS45 mice, 
carrying the Human G384A-mutated PS1 [41].   
In these mice, deposition of senile plaques starts at ~ 6 weeks of age in the 
neocortex and at 2-3 months of age in the hippocampus (DG) and is followed by 
gliosis (hypertrophic astrocytes) at 6 months of age [42]. Mice show full blown 
plaque pathology in the cortex at an age of 8 months [43].  
The combination of these mutations leads to a high production of Aβ42, an 
impairment in cognitive functions and a reduced performance in the water maze 
test of mice at 6-8 months of age [22]. 
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1.7.2 PS45 mouse model 
 
PS45 mice overexpress human G384A-mutated PS1. Although this mutation also 
increases the production of Aβ42 [44], PS45 mice do not develop plaque 
pathology, neuroinflammation and do not show behavioral or cognitive alterations 
[41]. However, at 10-14 months of age PS45 mice exhibit a hyperactivity of 
neurons, comparable to disturbances in neuronal network in AD mice at the same 
age [32]. 
 
1.8  Summary and Project Aims 
 
In summary, there is evidence for a positive correlation between amyloidosis and 
an altered GABA content in astrocytes surrounding amyloid plaques in the 
hippocampus. Different studies have shown that pathological GABA release from 
astrocytes under these circumstances can affect neuronal network activity 
leading to tonic inhibition in the hippocampus. However, it is unclear whether 
astrocytes accumulate GABA also in other brain regions during amyloidosis and 
how the enhanced GABA content changes during disease progression. 
Furthermore, it is not known if astrocytic GABA content is also affected during the 
mild inflammatory reaction, which is found in the aged brain. 
 
In the current project we aimed at filling these gaps by asking following specific 
questions: 
 
1. Does astrocytic GABA accumulation take place exclusively in the 
hippocampus or can this phenomenon be found in other areas of the brain 
in AD mice? 
2. Is GABA accumulation in astrocytes linked to the aging process in WT 
mice? 
3. Does GABA reactivity of astrocytes depend on the presence of amyloid 
plaques? 
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2. Material & Methods 
 
Mice 
All experimental procedures were performed in accordance with regulations set 
by the government of Baden-Württemberg, Germany (PY 7/08, PY 1/16, PY 3/13, 
PY 9/11).                                                       
1-2 months (n=5), 4-6 months (n=5) and 9-10 months old (n=5) transgenic 
APP23xPS45 mice, age-matched WT C57BL/6 mice (2 months, n=5; 4-6 months, 
n=5; 9-11 months, n=6) and PS 45 mice (4-6 months, n =5) were used for 
experiments. Also, WT C57BL/6 mice (n=5) at 18-20 months of age were used. 
Both APPx23PS45 mice and PS45 mice were raised on a C57BL/6 background. 
APP23xPS45 is a double transgenic mouse line which is generated by crossing 
APP23 mice, carrying the human APP Swedish (670/671) mutation [40] with PS 
45 mice, carrying the Human G384A-mutated PS1 [41].  Expression of these 
mutated genes, which also lead to dementia in humans, cause the enhanced 
production of Aβ42, a toxic form of amyloid that is highly prone to aggregation.  
Deposition of senile plaques starts at 6 weeks of age in the neocortex and at 2-3 
months of age in the hippocampus (DG). Mice show full blown plaque pathology 
in the cortex at an age of 8 months [43].  At an age of 6-8 months, mice exhibit 
impairment in cognitive functions as shown by reduced performance in the water 
maze test [22]. PS 45 mice, carrying the Human G384A-mutated PS1, do not 
develop plaque pathology and show no behavioral or cognitive alterations [41]. 
All mice were housed in the animal facility at the Pharmacology and Toxicology 
Institute, University of Tübingen. Mice had free access to food and water and 
were kept under a 12-hour light/ dark cycle. 
 
Tissue preparation  
Transcardial perfusion was performed to preserve the integrity of the brain tissue. 
Mice were anesthetized by intraperitoneal injections of Ketamine (50 mg/ml) and 
Xylazine (20 mg/ml) at a ratio of 1:1, depending on the animal’s weight (10 mg/kg 
bodyweight).                                                                                                                                 
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Mice were transcardially perfused with cold phosphate buffered saline (PBS), 
followed by 4% formaldehyde (FA). Afterwards, the brain was removed and 
placed in 4% FA at 4°C overnight. After deposition in 25% sucrose for 24 hours, 
the brain was embedded in Tissue-Tek (Tissue Tek®) and frozen on dry ice. 
Tissue was kept at -80 C° until further use. 
 
Immunohistochemistry 
Sagittal brain slices of 50 µm thickness were cut using a cryotome (Leica 
CM1950). Slices were washed in PBS, blocked in 10% normal donkey serum 
(NDS) for 2 hours at room temperature, and transferred to the primary antibody 
solution (primary antibody in 2% NDS/ 1% Triton-x-100/ PBS) for 60 hours at 
room temperature. The primary antibodies used in our protocol were mouse anti-
S100β (Abcam) at a dilution of 1:200 and rabbit anti-GABA (Immunostar) at a 
dilution of 1:2000. 
Next, slices were washed in PBS and transferred into the secondary antibody 
solution (secondary antibody in 2% NDS/ 1% Triton-x-100/ PBS) for 1,5 hours. 
Secondary antibodies used were donkey anti-mouse 488 (Mobitec) at a dilution 
of 1:200 and donkey anti-rabbit Alexa 594 (Invitrogen) at a dilution of 1:1000. 
Slices were washed in PBS and mounted on glass slides with VectaShield 
mounting media (Vector laboratories). Glass coverslips were fixed to superfrost 
glass slides with nail varnish around the edges. Fibrillar amyloid deposits were 
visualized by counterstaining slices with 1x10‾6 Thioflavin-S (Sigma-Aldrich) in 
PBS for 5 minutes. 
 
Imaging and Analysis 
Two-photon images of immunofluorescent antibody staining were recorded with 
an x40 water immersion objective (Zeiss), 0.8 N.A., in the cortex, hippocampus 
and olfactory bulb (OB) using a custom-built two-photon laser scanning 
microscope, with a mode-locked laser (MaiTai, Spectra Physics) working at 690-
1040 nm. The laser was connected to an Olympus FV300 laser scanning system 
and an Olympus BX51WI microscope. 
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All fluorophores were excited at 800 nm and emitted light was collected with two 
separate photomultiplier tubes. Emitted light from S100β-Alexa488 and GABA-
Alexa594 was collected using a 585 nm secondary dichroic mirror, splitting 
emitted light into two channels. Additionally, a 536/40 nm bandpass filter and a 
568 nm longpass filter were used to exclude the emission light with the wrong 
wavelength. Fluorescence from S100β-Alexa488 was collected by PMT1, while 
fluorescence from GABA-Alexa594 was collected by PMT2. 
Emitted light from Thioflavin-S was collected by using a different secondary 
dichroic mirror (515 nm). Emitted light was collected in the 420-520 nm 
wavelength range by using an additional barrier filter. Additionally, a 470/100 nm 
bandpass filter was used to exclude the emission light with the wrong wavelength. 
512x512 pixel, 16-bit z-stack TIFF images were acquired at x 2 magnification, 1 
µm z-axis intervals and averaged over 3 frames. 
To measure GABA intensity in astrocytes, maximum GABA intensity projection 
images were created with 4-12 slice thick z-stack images for every analyzed cell. 
The top and bottom slice where the cell of interest appears first determined the 
boundaries of the z-stack. Next, a region of interest (ROI) was drawn around the 
astrocyte in the S100β channel. Subsequently, three background ROIs were 
drawn in the GABA channel and fluorescence intensity of all four ROIs was 
measured in the GABA channel. 
Normalized GABA intensity was calculated as follows:  
Normalized GABA intensity = cell GABA intensity / average background intensity 
Image analysis and analysis were made in Fiji (https://imagej.net/Fiji). 
 
Defining different cell types 
In the 4-6 months age group of AD mice, astrocytes were divided into two different 
groups, depending on their distance from the nearest amyloid plaque. As various 
pathological alterations in different cell types have been described to occur within 
a radius of 50-60 µm from amyloid plaques [22, 45], we chose to define the area 
located ≤ 60µm from plaques as plaque vicinity. 
Astrocytes that were located ≤ 60 µm from the nearest plaque were defined as 
“near the plaque” cells and astrocytes that are located > 60 µm from the nearest 
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plaque were defined as “far from plaque” cells. The 60 µm radius was set from 
the edge of the plaque to the centre of the cell somata. A plaque was defined as 
a Thioflavin-S positive amyloid deposit if its diameter exceeded 5 µm. 
 
Statistics 
Statistical analyses were performed using the VassarStats Statistical 
Computation Website (http://vassarstats.net/), Excel (Microsoft, Redmond, WA, 
USA), and MATLAB (The MathWorks, Natick, MA, USA). Data are shown as 
median ± interquartile range, if not indicated otherwise. Lines of box plots 
represent 25th and 75th, whiskers 10th and 90th percentiles. 
Shapiro-Wilk test was used to test data sets for normality. As all relevant data 
sets were distributed normally, Student's t-test was used for comparison of two 
data sets. For comparison of three data sets, one-way ANOVA followed by a post-
hoc Bonferroni correction for multiple comparisons was used for normally 
distributed data, and Kruskal-Wallis test followed by a post-hoc Dunn’s correction 
for multiple comparisons was used for data that was not normally distributed. 
Differences between the groups were regarded as significant if p-values were 
below 0.05. Spearman's rank correlation coefficient (rS) was used to analyze the 
correlation between soma size and GABA intensity. If p-values were below 0.05, 
correlation was regarded as significant. 
Distribution of astrocytic soma size and GABA intensity in the analyzed 
population of cells was compared between different groups using the 
Kolmogorov-Smirnov test. Differences between the groups were regarded as 
significant if p-values were below 0.01. 
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3. Results 
 
In this study, size and GABA content of astrocytes in cortical layers 2/3, olfactory 
bulb and DG of amyloid-depositing and WT mice were examined in fixed brain 
slices using two-photon microscopy. Since we aimed to observe plaque-
dependent changes in astrocytes we chose the following age groups: 1-2 months, 
at this age no plaque depositions have developed yet; 4-6 months, starting phase 
of plaque deposition; and 9-11 months, where plaques are vastly abundant 
throughout the cortex and DG. We also included 18-20 months old WT mice, 
allowing us to make observations about astrocytic changes during the healthy 
aging process. 
We analyzed soma size and GABA content, as they are well-known parameters 
characterizing a reactive astrocyte and are known to be affected by amyloidosis.  
 
3.1 Astrocytes in the hippocampus of amyloid-depositing mice show 
GABA reactivity  
 
First, we examined hippocampal astrocytes of amyloid-depositing mice, as it has 
been shown that astrocytic GABA reactivity can be found in this brain region in 
other mouse models of AD.  
In images of 4-6 months and 9-11 months old mice (Fig. 1, middle and lower row), 
astrocytes could clearly be identified in the GABA channel (red; second and third 
row) and a colocalization of S110β (green) and GABA could be seen in the 
merged images on the right. Furthermore, Thioflavin-S positive plaque formations 
were evident (blue; third row) as mice age, while no amyloid plaques and 
colocalization could be found in 1-2 months old mice (upper row). 
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Figure 1: Hippocampal astrocytes of amyloid-depositing mice show significant GABA reactivity. 
Maximum-intensity projection obtained from the hippocampus (DG) in a fixed brain slice of an 
amyloid-depositing mouse at 2 months (upper row, 15 slices, step size 1 µm), 6 months (middle 
row, 15 slices, step size 1 µm) and 11 months (bottom row, 14 slices, step size 1 µm) of age, 
respectively. Brain slices were labeled with antibodies against S100β (green; left panel), GABA 
(red; middle panel) and with Thioflavin-S (blue; right panel). In the merged images on the right, 
S100β-positive astrocytes are indicated by white arrows and GABA-positive interneurons are 
indicated by orange triangles. Scale bar 20 µm. 
 
We found a trend towards increase in median (per mouse) soma size in the 
course of amyloid deposition, however, this trend did not reach statistical 
significance (Fig. 2A left panel; p= 0.308, one-way ANOVA). Comparing median 
normalized GABA intensity between different age groups, we not only found an 
astrocytic accumulation of GABA at 4-6 months, as previously reported, but also 
an up-and-down trend in GABA values with a significant increase from 1-2 
months to 4-6 months (Fig. 2A right panel; p < 0.01*; one-way ANOVA followed 
by a post-hoc Bonferroni correction for multiple comparisons) and a significant 
decrease from 4-6 months to 9-11 months (Fig. 2A right panel; p<0.01*; post-hoc 
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Bonferroni correction for multiple comparisons). A difference between astrocytic 
GABA levels in 1-2 months and 9-11 months old mice was not significant 
(p=0.361; post-hoc Bonferroni correction for multiple comparisons). 
Cumulative distribution of soma size showed a similar development with a shift 
to the right from 1-2 months to 4-6 months (Fig. 2A left panel; p<0.01*, 
Kolmogorov-Smirnov test), while there was no significant difference between 4-6 
months and 9-11 months (p=0.02).  
A prominent shift was also visible from 1-2 months to 9-11 months (p<0.01, 
Kolmogorov-Smirnov test). 
For normalized GABA intensity, an up-and-down trend was visible with a 
prominent shift to the right solely in the 4-6 months age group, then dropping to 
lower values in 9-11 months old mice (Fig. 2B, right panel; p<0.01* for all 
comparisons, Kolmogorov-Smirnov test). 
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Figure 2: In amyloid-depositing mice, hippocampal astrocytes show significant changes  
in soma size and GABA content throughout the aging process. This figure was reproduced from 
Brawek et al. (2018) [46]. 
A: Box-and-whisker plots showing median soma size (left) and normalized GABA intensity (right) 
of hippocampal astrocytes in amyloid-depositing mice at 1-2 months (red; n=5 mice), 4-6 months 
(blue; n=5 mice) and 9-11 months (green; n=5 mice) of age.  Both soma size and normalized 
GABA intensity increased from 1-2 months old mice to 4-6 months old mice, then decreased in 
the 9-11 months age group (p=0.308 for “soma size”; p<0.01* for “normalized GABA intensity”, 1-
2 vs 4-6 and 4-6 vs 9-11 p<0.05*, 1-2 vs 9-11 p=0.361; one-way ANOVA). 
B: Distribution of soma size (left) and normalized GABA intensity (right) of hippocampal astrocytes 
in amyloid-depositing mice at 1-2 months (red; 200 cells), 4-6 months (blue; 199 cells) and 9-11 
months (green; 195 cells) of age, displayed by cumulative probability histograms. Compared to 
1-2 months old mice, 4-6 months and 9-11 months old mice reached higher values in soma size. 
GABA intensity was strongly shifted from 1-2 months to 4-6 months old mice, then back to lower 
levels in the 9-11 months age group (1-2 vs 4-6 and 1-2 vs 9-11 p<0.01*, 4-6 vs 9-11 p=0.02 for 
“soma size”; p<0.01* for “Normalized GABA intensity”; Kolmogorov-Smirnov-Test).  
 
These results show a bell-shaped dependence of GABA content in hippocampal 
astrocytes on mouse age and suggest that GABA accumulation and cell 
hypertrophy are regulated by separate mechanisms. 
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3.2 Cortical astrocytes show bell-shaped GABA reactivity during 
amyloidosis  
 
To find out whether this observation is only true for the DG or if it also true for 
other parts of the mouse brain, we examined astrocytes in the frontal cortex of 
AD mice, since this region undergoes strong amyloidosis both in mice and 
humans. 
Again, there was plaque formation and colocalization of S100β and GABA 
reactivity in the plaque vicinity in images of 4-6 months and 9-11 months old mice 
(Fig. 3A, third and fourth row), while none was visible in 1-2 months old animals 
(first row). 
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Figure 3: Cortical astrocytes of amyloid-depositing mice show significant GABA reactivity. 
Maximum-intensity projection images obtained from the frontal cortex in a fixed brain slice of an 
amyloid-depositing mouse at 2 months of age (upper row, 14 slices, step size 1 µm), 6 months 
(middle row, 12 slices, step size 1 µm) and 11 months of age (bottom row, 18 slices, step size 1 
µm). Brain slices were labeled with antibodies against S100β (green; left panel), GABA (red; 
middle panel) and with Thioflavin-S (blue; right panel). In the merged images on the right, S100β-
positive astrocytes are indicated by white triangles and GABA-positive interneurons are indicated 
by orange triangles. Scale bar 20 µm. 
 
We found that median soma size increased continuously with age, with a 
significant difference between 1-2 months age group and both 4-6 months and 9-
11 months age groups, and no difference between 4-6 months and 9-11 months 
age groups (Fig. 4A, left panel; 1-2 months vs. 4-6 months and 1-2 months vs. 9-
11 months p<0.01*, 4-6 vs. 9-11 p=0.661; one-way ANOVA). Similar to the data 
obtained for DG, median GABA intensity also increased significantly from 1-2 
months to 4-6 months (Fig. 4A, right panel; 1-2 vs. 4-6 p<0.01*; one-way ANOVA) 
yet decreased significantly from 4-6 months to 9-11 months of age (Fig. 4A, right 
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panel; 4-6 vs. 9-11 p<0.01*; one-way ANOVA). A difference between GABA 
levels in 1-2 months and 9-11 months was not detectable (Fig. 4A, right panel; 1-
2 vs. 9-11 p=1; one-way ANOVA). Comparing the different age groups on the 
population level endorsed the notion that soma size increases in the course of 
aging (Fig. 4B, left panel; p<0.01*; Kolmogorov-Smirnov test). On the other hand, 
normalized GABA intensity values showed an up-and-down trend with the highest 
values observed in 4-6 months old mice (Fig. 4B, right panel; p<0.01* for all 
comparisons; Kolmogorov-Smirnov test). 
 
Figure 4: In amyloid depositing mice, cortical astrocytes show significant changes in soma size 
and GABA content throughout the aging process. This figure was reproduced from Brawek et al. 
(2018) [46]. 
A: Box-and-whisker plots showing median soma size (left) and normalized GABA intensity (right) 
of cortical astrocytes in amyloid-depositing mice at 1-2 months (red; n=5 mice), 4-6 months (blue; 
n=5 mice) and 9-11 months (green; n=5 mice) of age. Soma size continuously increases with 
age, while there was a clear up-and-down trend in normalized GABA intensity (1-2 vs 4-6 and 1-
2 vs 9-11 p<0.01*, 4-6 vs 9-11 p=0.661 for “soma size”; 1-2 vs 4-6 and 4-6 vs 9-11 p<0.01*, 1-2 
vs 9-11 p=1 for “normalized GABA intensity”; one-way ANOVA). 
B: Distributions of soma size (left) and normalized GABA intensity (right) of cortical astrocytes in 
amyloid-depositing mice at 1-2 months (red; 213 cells), 4-6 months (blue; 513 cells) and 9-11 
months (green; 225 cells) of age, displayed as cumulative probability histograms. Compared to 
1-2 months old mice, soma size increased in both 4-6 months and 9-11 months old mice (p<0.01*; 
Kolmogorov-Smirnov-Test). GABA intensity increased strongly from 1-2 months to 4-6 months 
old mice (p<0.01*; Kolmogorov-Smirnov-Test), then reached lower levels in the 9-11 months age 
group (p<0.01*; Kolmogorov-Smirnov-Test). 
 
  
 28 
These results show a bell-shaped development of GABA content in astrocytes 
during the course of amyloidosis in the frontal cortex, comparable to that seen in 
the DG, again suggesting that during aging GABA accumulation and cell 
hypertrophy are regulated by separate mechanisms. 
 
3.3 Cortical astrocytes show GABA reactivity exclusively in the vicinity of 
amyloid plaques 
 
Next, we decided to elaborate on possible reasons for hypertrophy and GABA 
reactivity in cortical astrocytes of amyloid-depositing mice at 4-6 months of age. 
Therefore, we classified astrocytes dwelling at a distance less than 60 µm from 
the nearest amyloid deposition as located in “plaque vicinity“ and those located 
more than 60 µm away as “far from plaque“ and measured GABA intensity and 
soma size (Fig. 5). 
Because at 4-6 months the plaque deposition in the frontal cortex of amyloid-
depositing mice is present but not ubiquitous, this age group was chosen to 
distinguish between astrocytes close and far from plaques. In contrast, at an age 
of 9-11 months plaques were vastly abundant throughout the cortex and virtually 
all astrocytes were located less than 60 µm away from the closest amyloid 
deposition.  
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Figure 5: Cortical astrocytes of amyloid-depositing mice at 6 months of age show significant 
GABA reactivity in the vicinity of amyloid plaques. 
Maximum-intensity projection images (4-6 months “far” = 16 slices, 4-6 months “plaque vicinity” 
= 16 slices) obtained from the frontal cortex in a fixed brain slice of an amyloid-depositing mouse 
at 6 months of age “far from plaque” (upper row, 16 slices, step size 1 µm) and “plaque vicinity” 
(lower row, 16 slices, step size 1 µm). Brain slices were labeled with antibodies against S100β 
(green; left panel), GABA (red; middle panel) and with Thioflavin-S (blue; right panel). In the 
merged images on the right, S100β-positive astrocytes are indicated by white triangles and 
GABA-positive interneurons are indicated by orange triangles. Scale bar 20 µm. 
 
Similarly, we were not able to differentiate between astrocytes that are located 
close and far from plaque in the DG, due to the high plaque load in this area.  
Colocalization of GABA and S100β was evident in images showing astrocytes in 
”plaque vicinity“ (Fig. 5 upper row), no colocalization was seen in astrocytes „far 
from plaque“ (Fig. 5 lower row). 
An increase in both astrocytic soma size (Fig. 6A and B, left panels) and GABA 
content (Fig. 6A and B, right panels) occurred only in cells located in „plaque 
vicinity“ compared to astrocytes located „far from plaque” (Fig. 6A; p<0.01* for 
“soma size” and p<0.01* for “normalized GABA Intensity”; Student’s T-test; Fig 
6B; p<0.01* for “soma size” and p<0.01* for “normalized GABA Intensity”; 
Kolmogorov-Smirnov-Test).  
Furthermore, soma size and GABA content of cells located ”far from plaque“ were 
comparable to values of WT mice at the same age (Fig. 6B; soma size: p = 0.691; 
GABA content: p = 0.176; Kolmogorov-Smirnov-Test).   
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Figure 6: Cortical astrocytes located in “plaque vicinity” show a significant difference in soma size 
and normalized GABA intensity compared to astrocytes located “far from plaque” at 4-6 months 
of age. This figure was reproduced from Brawek et al. (2018) [46]. 
A: Box-and-whisker plots showing median soma size (left; n=5 mice) and normalized GABA 
intensity (right; n=5 mice) of cortical astrocytes in amyloid-depositing mice at 4-6 months of age, 
separated into astrocytes located “far from plaque” (green) and in “plaque vicinity” (red). 
Significant differences were visible for both parameters (p<0.01* for “soma size” and p<0.01* for 
“normalized GABA Intensity”; Student’s T-test). 
B: Distributions of soma size (left) and normalized GABA intensity (right) of cortical astrocytes in 
amyloid-depositing and WT mice at 4-6 months of age, displayed as cumulative probability 
histograms. Astrocytes of amyloid-depositing mice were separated into astrocytes located “far 
from plaque” (green; 200 cells) and astrocytes located in “plaque vicinity” (red; 313 cells). While 
astrocytes located “far from plaque” showed no difference in soma size and normalized GABA 
intensity values compared to WT astrocytes (p=0.176 for “normalized GABA intensity” and 
p=0.691 for “soma size”; Kolmogorov-Smirnov-Test), astrocytes located in “plaque vicinity” 
showed a significant difference in both parameters compared to astrocytes in WT mice (p<0.01* 
for all comparisons; Kolmogorov-Smirnov-Test). 
 
Furthermore, there was a positive correlation between the two parameters at 4-6 
months of age both in the cortex as well as in the DG (Fig. 7; rS=0.51, p<0.0001 
in the cortex; rS=0.16, p=0.021 in the hippocampus; Spearman correlation), while 
there was no correlation in the 9-11 months age group neither for cortical nor for 
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hippocampal astrocytes (Fig 7; rS=0.014, p=0.842 in the cortex; rS=0.066, 
p=0.364 in the DG; Spearman correlation).  
 
 
Figure 7: Normalized GABA content is correlated with soma size only in 4-6 months-old amyloid 
depositing mice. This figure was reproduced from Brawek et al. (2018) [46]. 
Scatter plots showing astrocytic GABA content as a function of soma size in the cortex (left) and 
in the hippocampus (right) of 4-6 months (blue; n=5 mice) and 9-11 months old (red; n=5 mice) 
amyloid-depositing mice. At 4-6 months of age, there was a positive correlation between soma 
size and GABA content (rS=0.51, p<0.0001 in the cortex; rS=0.16, p=0.021 in the hippocampus; 
Spearman correlation). In 9-11 months old mice, these parameters were not correlated (rS=0.014, 
p=0.842 in the cortex; rS=0.066, p=0.364 in the hippocampus; Spearman correlation). 
 
This leads to the assumption that the processes causing astrocytic hypertrophy 
and GABA accumulation have a common trigger during the early stages of 
amyloidosis, while at 9-11 months, when plaques are vastly abundant throughout 
the cortex, they are governed by different processes. 
 
3.4 Astrocytic GABA content in the course of healthy aging  
 
After we found GABA reactivity in different brain areas of amyloid-depositing 
mice, we wondered whether this process also occurs in normally aging WT mice. 
So, we analyzed astrocytes in 1-2, 4-6, 9-11 and 18-20 months old WT mice in 
the cortex and in the DG.  
Images from the DG showed only modest colocalization of S100β and GABA 
reactivity in all age groups examined (Fig. 8). 
  
 32 
 
Figure 8: Hippocampal astrocytes of WT mice show little GABA reactivity. 
Maximum-intensity protection images obtained from the hippocampus (DG) in a fixed brain slice 
of an WT mouse at 2 months (first row, 13 slices, step size 1 µm), 5 months (second row, 7 slices, 
step size 1 µm), 11 months (third row, 16 slices, step size 1 µm) and 19 months (bottom row, 14 
slices, step size 1 µm) of age, respectively. Brain slices were labeled with antibodies against 
S100β (green; left panel) and GABA (red; middle panel). In the merged images on the right, 
S100β-positive astrocytes are indicated by white triangles and GABA-positive interneurons are 
indicated by orange triangles. Scale bar 20 µm. 
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Similar data were obtained in the frontal cortex (Fig. 9). 
 
 
Figure 9: Cortical astrocytes in WT mice show little GABA reactivity. 
Maximum-intensity projection images obtained from the frontal cortex in a fixed brain slice of an 
WT mouse at 2 months (first row, 19 slices, step size 1 µm), 5 months (second row, 21 slices, 
step size 1 µm), 9 months (third row, 12 slices, step size 1 µm) and 19 months (bottom row, 12 
slices, step size 1 µm) of age, respectively. Brain slices were labeled with antibodies against 
S100β (green; left panel) and GABA (red; middle panel). In the merged images on the right, 
S100β-positive astrocytes are indicated by white triangles and GABA-positive interneurons are 
indicated by orange triangles. Scale bar 20 µm. 
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Comparing astrocytic soma size between the two brain structures, cortical 
astrocytes were significantly larger than hippocampal astrocytes in all age groups 
(p = 0.0001 for 1-2 months; p = 0.0007 for 4-6 months; p = 0.006 for 9-11 months; 
Student’s t-test), except for astrocytes in 18-20 months old mice (p=0.83; 
Student’s t-test).  
In the DG, median astrocytic soma size at 18-20 months of age was significantly 
larger than in all other age groups (Fig. 10A, left panel; p = 0.001; 18-20 months 
vs. 1-2 months, 4-6 months, and 9-11 months: p < 0.001 for all comparisons; one-
way ANOVA followed by post-hoc Bonferroni correction for multiple 
comparisons).  
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Figure 10: Cortical astrocytes in WT mice show minor differences in GABA content and soma 
size in the course of aging. This figure was reproduced from Brawek et al. (2018) [46]. 
A: Box-and-whisker plots showing median soma size (left) and normalized GABA intensity (right) 
of cortical astrocytes in WT mice at 1-2 months (red; n=5 mice), 4-6 months (blue; n=5 mice), 9-
11 months (green; n=5 mice) and 18-20 months (light blue; n=5 mice) of age. There was no 
change of both parameters during the aging process (p=0.155 for “soma size” and p=0.919 for 
“normalized GABA intensity”; one-way ANOVA).  
B: Distributions of soma size (left) and normalized GABA intensity (right) of cortical astrocytes in 
WT mice at 1-2 months (red; n=301 cells), 4-6 months (blue; n=514 cells), 9-11 months (green; 
n=226 cells) and 18-20 months (light blue; n= 200 cells) of age, displayed as cumulative 
probability histograms. Comparing different age groups, distribution of soma size in 1-2 months 
and 18-20 months old mice were significantly shifted to the right when compared to that of 4-6 or 
9-11 months old mice (p < 0.01 for all comparisons, Kolmogorov-Smirnov test), while distribution 
of GABA intensity was significantly higher in 9-11 months old mice compared to 1-2 months old 
mice (p = 0.004, Kolmogorov-Smirnov test; p > 0.01 for all other comparisons). Astrocytes in 18-
20 months old mice were not significantly different from all other age groups (p > 0.01 for all 
comparisons, Kolmogorov-Smirnov test).  
 
On the other hand, median soma size of cortical astrocytes did not increase 
during the course of aging (Fig. 11A, left panel; p= 0.27; one-way ANOVA). 
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Aging did not significantly increase median astrocytic GABA levels in both cortical 
and hippocampal astrocytes (Fig. 10A and Fig 11A, right panels; in the cortex: p 
= 0.98; in the DG: 16, p = 0.14; one-way ANOVA). However, the normalized 
GABA intensity was significantly lower in hippocampal than in cortical astrocytes 
(1-2 months: p = 0.04; 4-6 months: p = 0.03; 18-20 months: p = 0.0004; Student’s 
t-test) except for astrocytes at 9-11 months of age (p = 0.195; Student’s t-test).  
A comparison of the different age groups on the population level (Fig. 10B and 
11B, left panels) showed that astrocytic soma size increased with age in the DG, 
again strikingly in the 18-20 months age group (p < 0.001 for comparisons to all 
other age groups; Kolmogorov-Smirnov test), whereas cortical astrocytes in 4-6 
months and 9-11 months old mice showed slightly but significantly smaller soma 
size than at 1-2 months and 18-20 months of age (p < 0.01; Kolmogorov-Smirnov 
test).                                  
The GABA content increased with age in both cortex and hippocampus (1-2 
months vs 9-11 months; in the cortex: p = 0.004; in the DG: p < 0.001; 
Kolmogorov-Smirnov test) but returned to lower values in 18-20 months old mice.  
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Figure 11: Significant changes in soma size in hippocampal astrocytes of WT mice in the course 
of aging. This figure was reproduced from Brawek et al. (2018) [46]. 
A: Box-and-whisker plots showing median soma size (left) and normalized GABA intensity (right) 
of hippocampal astrocytes in WT mice at 1-2 months (red; n=5 mice), 4-6 months (dark blue; n=5 
mice), 9-11 months (green; n=5 mice) and 18-20 months (light blue; n=5 mice) of age. Soma size 
increased significantly in 18-20 months old animals in comparison to all other age groups (p = 
0.001; one-way ANOVA; 18-20 months old animals compared to 1-2, 4-6, and 9-11 months old 
animals: p < 0.001 for all comparisons; comparisons between 1-2, 4-6, and 9-11 months old 
animals: p = 1 for all comparisons; post-hoc Bonferroni correction for multiple comparisons) 
whereas GABA levels were similar (p = 0.14, one-way ANOVA).  
B: Distributions of soma size (left) and normalized GABA intensity (right) of hippocampal 
astrocytes in WT mice at 1-2 months (red; n=200 cells), 4-6 months (dark blue; n=195 cells), 9-
11 months (green; n= 199 cells) and 19-20 months (light blue; n= 200 cells) of age, displayed as 
cumulative probability histograms. A significant shift to the right in 9-11 months old mice was 
visible compared to 4-6 months old mice (p = 0.004, Kolmogorov-Smirnov test), whereas there is 
no difference between 1-2- and 4-6-months old mice and 1-2 and 9-11 months old mice (p > 0.01 
for both comparisons, Kolmogorov-Smirnov test). In 18-20 months old mice, this shift was even 
more prominent (p < 0.001 for all comparisons, Kolmogorov-Smirnov test). Small differences 
between 1-2 months and 9-11 months (p<0,01* for “Normalized GABA intensity“; Kolmogorov-
Smirnov-test) and 4-6 months and 9-11 months (p<0,01* for “soma size“; Kolmogorov-Smirnov-
test) could be found. Distribution of the normalized GABA intensity was significantly shifted to the 
left in 18- 20 months old animals compared to all other age groups (p < 0.001 for all comparisons, 
Kolmogorov-Smirnov test).  
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These results suggest that in healthy mouse brains there is a moderate GABA 
accumulation in astrocytes during adolescence in healthy mouse brains. Since 
age dependent changes in soma size and GABA content did not exhibit the same 
trend in cortex and DG, it’s more likely that they are not caused by the identical 
mechanisms. 
 
 
3.5 Age-dependent differences between WT and AD mice in cortex and 
hippocampus  
 
We also compared soma size and GABA content of AD and WT mice directly 
between the respective age groups and found that there are significant 
differences in both parameters during the course of aging. 
In the cortex of 4-6 months old mice, there was a significant increase in astrocytic 
soma size in astrocytes located in “plaque vicinity” compared to astrocytes from 
age-matched WT mice (Fig. 12A, middle panel; p<0.01*; Kolmogorov-Smirnov-
Test). Astrocytic soma size was also significantly increased in AD mice at 9-11 
months of age compared to respective astrocytes in WT mice (Fig. 12A, right 
panel; p<0.01*; Kolmogorov-Smirnov-Test).  
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Figure 12: Cortical astrocytes in AD mice show age-dependent differences in soma size and 
GABA content compared to that of WT mice.  
A: Distribution of soma size of cortical astrocytes at 1-2 months (left), 4-6 months (middle) and 9-
11 months (right) of age, respectively, displayed as cumulative probability histograms. Astrocytes 
of AD mice (red; n= 213 cells 1-2 months, n= 513 cells 4-6 months, n= 225 cells 9-11 months) 
were compared to astrocytes of WT mice (black; n= 301 cells 1-2 months, n=514 cells 4-6 months, 
n= 226 cells 9-11 months) at the respective age. In the 4-6 months age group there was a 
significant difference in soma size between astrocytes located in “plaque vicinity” (green; n= 313 
cells) and astrocytes located “far from plaque” (red; n=200 cells; p<0.01*; Kolmogorov-Smirnov-
Test), whereas astrocytes located “far from plaque” had the same size as astrocytes of WT mice 
(p=0.691; Kolmogorov-Smirnov-Test). Also, there was a significant difference in soma size in the 
9-11 months age group (p<0.01*; Kolmogorov-Smirnov-Test) and a small but significant 
difference in the 1-2 months age group between astrocytes of AD mice and WT mice (p< 0.01*; 
Kolmogorov-Smirnov-Test). 
B: Distributions of normalized GABA intensity of cortical astrocytes at 1-2 months (left), 4-6 
months (middle) and 9-11 months (right) of age, respectively, displayed as cumulative probability 
histograms. Astrocytes of AD mice (red; n= 213 cells 1-2 months, n= 513 cells 4-6 months, n= 
225 cells 9-11 months) were compared to astrocytes of WT mice (black; n= 301 cells 1-2 months, 
n=514 cells 4-6 months, n= 226 cells 9-11 months) at the respective age. Astrocytes of AD mice 
at 4-6 months of age located in “plaque vicinity” (green; n= 313 cells) had a higher normalized 
GABA intensity than astrocytes located “far from plaque” (red; n=200 cells; p<0.01*; Kolmogorov-
Smirnov-Test) and astrocytes of WT mice (p<0.01*; Kolmogorov-Smirnov-Test). 
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For normalized GABA intensity, there was a significant shift in GABA levels in 
astrocytes located in “plaque vicinity” in AD mice compared to astrocytes of WT 
mice at 4-6 months of age (Fig. 12B, middle panel; p<0.01*; Kolmogorov-
Smirnov-Test).  
Additionally, median astrocytic GABA levels at 9-11 months in AD mice showed 
no difference to GABA levels in WT mice at the same age (Fig. 13, lower row; p 
= 0.74; Student’s t-test;). 
 
Figure 13: Cortical astrocytes of AD and WT mice show differences in soma size and GABA 
content in the cortex. This figure was reproduced from Brawek et al. (2018) [46]. Box-and-
whisker plots comparing median soma size (upper panel) and normalized GABA intensity 
of astrocytes in the cortex of 1-2 months (left panel), 4-6 months (middle panel), and 9-
11 months (right panel) old WT (black) and AD (red) mice.  Both values were significantly 
higher in 4-6 months old amyloid depositing mice (soma size: p = 0.03; GABA intensity: 
p = 0.04; Student’s t-test), while values in 1-2 months old pre-depositing mice were 
similar (soma size: p = 0.18; GABA intensity: p = 0.69; Student’s t-test). Median soma 
size was significantly larger in AD mice at 9-11 months of age (p = 0.0009; Student’s t-
test), whereas median normalized GABA intensities were similar (p = 0.74; Student’s t-
test).  
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Similar results were found for the hippocampus. Across all ages, there was a 
significant difference in astrocytic soma size comparing AD and WT mice (Fig. 
14A; p<0.01* for all comparisons; Kolmogorov-Smirnov-Test). 
 
 
Figure 14: Hippocampal astrocytes in AD mice show age-dependent differences in soma size 
and GABA content compared to that of WT mice. 
A: Distributions of soma size of hippocampal astrocytes at 1-2 months (left), 4-6 months (middle) 
and 9-11 months (right) of age, respectively, displayed as cumulative probability histograms. 
Astrocytes of amyloid-depositing mice (red; n= 200 cells 1-2 months, n= 199 cells 4-6 months, n= 
195 cells 9-11 months) were compared to astrocytes of WT mice (black; n= 200 cells 1-2 months, 
n= 195 cells 4-6 months, n= 199 cells 9-11 months) at the respective age. There was a significant 
difference in soma size between astrocytes of AD mice and astrocytes of WT mice in all age 
groups (p<0,01*; Kolmogorov-Smirnov-Test); however, the soma size value increased from 1-2 
months to 4-6 months and then decreased from 4-6 months to 9-11 months in amyloid-depositing 
mice. 
B: Distributions of normalized GABA intensity of hippocampal astrocytes at 1-2 months (left), 4-6 
months (middle) and 9-11 months (right) of age, respectively, displayed as cumulative probability 
histograms. Astrocytes of AD mice (red; n= 200 cells 1-2 months, n= 199 cells 4-6 months, n= 
195 cells 9-11 months) were compared to astrocytes of WT mice (black; n= 200 cells 1-2 months, 
n= 195 cells 4-6 months, n= 199 cells 9-11 months) at the respective age. There was no significant 
difference in normalized GABA intensity in the 1-2 months age group between astrocytes of AD 
mice and astrocytes of WT mice (p=0,027; Kolmogorov-Smirnov-Test), while the difference was 
significant in both 4-6 months and 9-11 months old mice (p<0,01*; Kolmogorov-Smirnov-Test). 
Comparing normalized GABA intensity in AD mice in the course of aging, it increased gravely 
from 1-2 months to 4-6 months and subsequently decreases in 9-11 months old mice.  
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For GABA intensity, there was a large difference between AD and WT mice at 4-
6 months of age (Fig. 14B, middle panel; p<0.01*; Kolmogorov-Smirnov-Test), 
while there was a small but significant difference comparing astrocytic GABA 
content in AD and WT mice at 9-11 months of age (Fig. 14B; p<0.01*; 
Kolmogorov-Smirnov-Test). 
Again, median astrocytic GABA levels at 9-11 months in AD mice showed no 
difference to GABA levels in WT mice of the same age (Fig. 15, lower row; p= 
0.38; Student’s t-test;). 
 
Figure 15: Astrocytes in AD and WT mice show differences in soma size and GABA content in 
the DG. This figure was reproduced from Brawek et al. (2018) [46].                  Box-and-whisker 
plots comparing median soma size (upper panel) and normalized GABA intensity of 
astrocytes in the DG of 1-2 months (left panel), 4-6 months (middle panel), and 9- 11 
months (right panel) old WT (black) and AD (red) mice. In pre-depositing mice at 1-2 
months of age, both parameters were similar (soma size: p = 0.06; GABA intensity: p = 
0.38; Student’s t-test). Values for soma size were similar in 4-6 months old mice (p = 
0.09; Student’s t-test), but GABA intensity was higher in AD mice (0 = 0.0001; Student’s 
t-test). Values for soma size were larger mice of 9-11 months of age (p = 0.0006; 
Student’s t-test), while median normalized GABA intensity compared to WT mice was 
similar (p = 0.38; Student’s t-test).  
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These results provide further evidence for the influence of amyloid formations on 
astrocytes and also for an up-and-down trend of astrocytic GABA content during 
the course of the disease. 
 
 
3.6 GABA reactivity can also be found without the presence of amyloid 
plaques 
 
Now that we found out that amyloid-depositions have an impact on astrocytic 
GABA levels and hypertrophy, we wanted to test if GABA accumulation can also 
appear in the absence of plaques. 
To this end, we decided to analyze astrocytes in 4-6 months old PS45 mice (Fig. 
16). In PS45 mice, mouse Aβ42 production is increased due to the expression of 
the AD-associated G384A mutation in PS1, but they do not show signs of 
inflammation or plaque-deposition. In the frontal cortex of these mice, we could 
identify moderate GABA accumulation in astrocytes (Fig. 16 lower row).  
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Figure 16: Cortical astrocytes in PS45 mice without amyloid deposition show GABA  
reactivity. 
Maximum-intensity projection images obtained from the frontal cortex in a fixed brain slice of an 
WT mouse at 5 months of age (upper row, 21 slices, step size 1 µm) and an PS45 mouse at 6 
months of age (bottom row, 15 slices, step size 1 µm). Brain slices were labeled with antibodies 
against S100β (green; left panel) and GABA (red; middle panel). In the merged images on the 
right, S100β-positive astrocytes are indicated by white triangles. Orange triangles indicate 
GABAergic interneurons. Scale bar 20 µm. 
  
Comparing median soma size, astrocytes of PS45 mice surprisingly had a 
significantly smaller median soma size than astrocytes in WT mice at the same 
age (Fig. 17A, left figure; p= 0.04*, Student’s t-test). There was a trend towards 
higher GABA levels in astrocytes of PS45 mice, however, it did not reach 
statistical significance (Fig. 17B, right panel; p= 0.11, Student’s t-test).  
Comparing the cumulative distributions of soma size and normalized GABA 
intensity, we found a significant shift in astrocytic GABA levels towards higher 
values in PS45 mice compared to WT mice (Fig. 17B, right panel; p<0.01*, 
Kolmogorov-Smirnov test), yet soma size was similar (Fig. 17B, left panel; p= 
0.104, Kolmogorov-Smirnov test).  
In both PS45 mice and WT mice, astrocytic soma size and GABA intensity were 
negatively correlated (Fig. 17C, Spearman's rank correlation coefficient for WT 
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mice rs =-0.237, p < 0.0001, for PS45 mice rs=-0.2551, p = 0.0001), leading to 
the assumption that, in this case, smaller astrocytes accumulate more GABA. 
 
 
Figure 17: Cortical astrocytes in PS45 mice show a difference in normalized GABA intensity, but 
no increase in soma size. This figure was reproduced from Brawek et al. (2018) [46]. 
A: Box-and-whisker plots showing median soma size (left) and normalized GABA intensity (right) 
of cortical astrocytes in WT mice (black, n=5 mice) and PS45 mice (orange; n=5 mice) at 4-6 
months of age. There was a slight but significant difference in soma size (p= 0.04’; Student’s T-
Test), but none in normalized GABA intensity (p= 0.156539; Student’s T-Test). 
B: Distribution of soma size (left) and normalized GABA intensity (right) of cortical astrocytes in 
WT mice (black; n= 195 cells) and PS45 mice (orange; n= 228 cells) at 4-6 months of age, 
displayed as cumulative probability histograms. While there was a significant difference in 
normalized GABA intensity between astrocytes in PS45 and WT mice (p<0.01*, Kolmogorov-
Smirnov-Test), there was no difference in soma size. 
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C: Scatter plots showing astrocytic GABA content as a function of soma size in the cortex of WT 
(black) and PS45 mutant mice (orange) at 4-6 months of age. There was a negative correlation 
between soma size and GABA intensity in both WT as well as PS45 mice (rS= - 0.2551, p<0.0001 
for PS 45 mice; Spearman correlation). 
 
These results show that an increase in astrocytic GABA content can also occur 
in the absence of amyloid plaques due to AD-related mutations in PS1 and that 
astrocytic hypertrophy and GABA content are controlled by different 
mechanisms. 
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4. Discussion 
Here, we studied two parameters of astrocytes known to be affected in the course 
of amyloidosis, soma size and GABA content. These parameters were studied in 
the cortex and hippocampal DG during plaque deposition in a mouse model of 
AD as well as during normal aging in WT mice.  
 
Three different key observations were made:  
 
1. Moderate but significant alterations in GABA content and soma size of 
astrocytes can be found during the normal aging process in the cortex and 
DG. 
2. Astrocytes in amyloid-depositing mice exhibit a bell-shaped dependence 
of GABA content on age during the course of amyloidosis in both cortex 
and DG, while astrocytic soma size continuously increases. 
3. Mice with a mutation in the PS1 gene devoid of amyloid plaque 
development show elevated astrocytic GABA content. 
 
It is well known that astrocytes exhibit distinct alterations in phenotype and 
function during the course of healthy aging [47-53]. As previously reported 
similarly for astrocytes in the hippocampal DG of 24-months old WT mice [47], 
we observed a small but significant increase in astrocytic soma size in mice 9-11 
months old mice, also in the DG. This increase becomes even more apparent at 
18-20 months old mice. Hence this leads to the assumption that an increase in 
soma size caused by the aging process begins during late adulthood and 
becomes even more apparent in the course of aging.  
Cortical astrocytes, however, exhibit minor alterations during aging with 
significant hypertrophy in aged mice after a decrease of soma size in early 
adulthood. 
Since we found an increase in astrocytic soma size in both the DG and cortex in 
aged mice compared to adult animals, this suggests that a hypertrophy of 
astrocytes is a byproduct of the aging-related moderate proinflammatory 
condition known to be present in the senescent brain [48-50].  
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The effect of aging on astrocytic phenotype and function is still unclear. Rodriguez 
et al. (2014) proposed that S100β, a Ca2+-binding protein expressed in astrocytes 
and presumably responsible for different types of neuro-glial interactions, may 
play a role [47]. Possibly S100β impairs cognition, and elevated levels of S100β 
were measured in the blood of aged humans affected with affected cognitive 
function. This assumption, however, needs additional confirmation [47]. An 
increase in soma size was also measured in astrocytes in the DG and entorhinal 
cortex (EC) of 24 old WT mice, however, no connection to an increase in 
astrocytic GABA content was made [47]. 
Grosche et al. (2013) studied morphological changes caused by the aging 
process in astrocytes in the hippocampus and cortex. They compared territories, 
covered by individual astrocytes in 5 months old and 21 months old WT mice and 
found an increase in territorial volume in cortical astrocytes and doubled territorial 
volume in hippocampal astrocytes [54].  
They proposed that this increase in territorial volume is caused by increased 
oxidative stress in the aging brain. Astrocytes, who are the predominant cells to 
prohibit oxidative stress in the brain and maintain this role also in senescent 
animals, possibly enlarge their domains to successfully clear reactive oxygen 
species that pile up as the brain ages.  
Although they did not report any alteration in soma size, it seems likely that soma 
size also increases with astrocytic territories during aging, which would fit to our 
data. An increase in astrocytic territory could also mean that more neurons and 
other cells like microglia can be contacted by astrocytes, thereby influencing 
network activity or the inflammatory response in the aging brain.  
Surprisingly, median soma size was larger in cortical astrocytes in all age groups 
studied when compared to astrocytes in the DG (except for 18-20 months old 
mice), providing further evidence for the regional variability of astrocytes which 
includes differences in morphological structure as well as physiological functions 
[51, 52].  
Astrocytic GABA content also exhibited modest but significant alterations during 
the course of normal aging. In the DG, the most obvious alteration was a 
significant increase in soma size in 18-20 months old mice compared to all other 
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age groups. In cortical astrocytes, however, no such prominent alteration was 
observed. 
A possible reason for this varying behavior of astrocytes in the cortex and 
hippocampus may be the different influence of network activities on astrocytes.  
Astrocytes are able to release neurotransmitters like GABA and glutamate. Since 
the release of these neurotransmitters can trigger small inward or outward 
currents when released [17, 18, 55], it is possible to assume that 
neurotransmitters released by astrocytes play an important role in maintaining 
neuronal network activity. 
In our AD mouse model, we see a gradual increase of soma size and plaque 
development in the cortex and hippocampus, with a peak soma size at the stage 
of severe amyloidosis (9-11 months), suggesting that amyloid deposition per se 
or associated factors are responsible for hypertrophy.  Surprisingly, astrocytic 
GABA content did not increase continuously with age. At 4-6 months of age, the 
starting phase of plaque formation, we measured surprisingly high astrocytic 
GABA values in the cortex and hippocampus. At 4-6 months of age in the cortex 
we found hypertrophic astrocytes with high GABA levels exclusively in the vicinity 
of amyloid plaques (closer than 60 µm), while astrocytes further away than 60 µm 
from the nearest amyloid plaque exhibited GABA levels and soma sizes 
comparable to those of WT mice. This leads to the assumption that at the 
beginning of AD, accumulation of GABA in astrocytes and astrocytic hypertrophy 
are caused by amyloid plaque formations. Both parameters were highly 
correlated at 4-6 months of age, supporting this theory. 
At 9-11 months of age, at the stage of the disease where plaques are vastly 
abundant throughout the brain, soma size continues to increase. In contrast, 
astrocytic GABA content did not follow this expected pattern but returned to 
GABA levels comparable to those before plaque deposition, both in the cortex 
and hippocampus. Additionally, soma size and GABA content were not correlated 
anymore in 9-11 months old mice. These observations indicate that astrocytic 
hypertrophy and accumulation of GABA are both triggered by the emergence of 
amyloid plaques but are actually two separate processes that take a different 
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development in the course of the disease. In fact, amyloid depositions do not 
further increase GABA in astrocytes as the disease progresses.      
Previous studies on astrocytic GABA accumulation in mouse models of AD only 
studied a specific age range and were therefore not able to uncover the bell-
shaped profile we see here [16, 20]. Additionally, they used different models of 
AD, which differ in the kinetics and severity of amyloidosis  [16, 20]. 
Wu et al. (2014) studied 5xFAD mice, in which development of pathology is 
comparable to our APP23xPS45 mouse model [11, 22, 56, 57]. Therefore, it is 
not surprising that they also report high astrocytic GABA levels at the age they 
studied (6-8 months), corresponding to the starting phase of plaque deposition. 
Jo et al. (2014), in contrast, observed elevated GABA levels in older mice at an 
age of 8- 13 months [16, 20]. However, as they used a different mouse strain 
(APPswe/PSEN1dE9) mice with a delayed and moderate plaque deposition [11], 
this age range probably similarly catches the beginning of amyloid pathology and 
the results are therefore not contradicting our own observations. 
The reason for the decrease in astrocytic GABA levels, which we found at later 
stages of the disease and the ensuing effects on neurons remains elusive. We 
suppose that astrocytic GABA accumulation and the associated release of GABA 
are ways to adapt to and to counteract neuronal hyperactivity, which is a known 
phenomenon associated with amyloid plaques already early during disease 
progression [22, 28, 29, 31, 58].  
Busche et al. (2008,2012) point out that neurons in both the cortex and 
hippocampus show hyperactivity in the vicinity of amyloid plaques [22, 29].  
The exact distance that separated hyperactive from normal or silent neurons was 
60 µm from the border of an amyloid plaque, which is the same distance that 
separated hypertrophic, reactive astrocytes from normal astrocytes in Jo et al. 
(2014) [20], and also the same distance we found that separates high-GABA 
astrocytes from low-GABA astrocytes, which further supports the hypothesis that 
astrocytic GABA accumulation could be a direct response to pathological network 
activity. 
However, it is surprising that we did not observe a constant increase in astrocytic 
GABA content along with the constant increase in amyloid depositions.  
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Furthermore, the mouse models used by Jo et al. (APPswe/PSEN1dE9) 
and Wu et al. (5xFAD) are also known to exhibit neuronal hyperactivity[57, 58]. 
The fact that these groups found GABA-reactivity of astrocytes in AD mouse 
models that also show disturbances in neuronal network can be a further sign 
that during the course of AD, astrocytes turn reactive to counterbalance the 
beginning of neuronal hyperactivity but are getting exhausted as the disease, as 
well as the severity of neuronal hyperactivity, progresses. 
Consistently, we also found GABA-positive astrocytes in PS45 mice, a mouse 
line devoid of amyloid depositions but with disturbances in the neuronal network 
[32], which are comparable to those found in AD mice.  
Lerdkrai et al (2018) found that during the aging process in both AD and WT mice, 
neuronal activity of cortical neurons is also enhanced, which could also be 
accompanied by elevated astrocytic GABA levels [32]. 
Based on these observations one can argue astrocytes reach two different 
functional stages in the course of AD: “fighting” astrocytes (increased GABA 
levels, large cell soma), appearing at the onset of amyloid deposition and the 
beginning of neuronal hyperactivity, and “frustrated” astrocytes (decrease in 
GABA content, large cell soma), appearing when plaques are vastly abundant 
throughout the brain. It can be argued that, although to a significantly lesser 
degree, astrocytes go through the same aforementioned development during 
normal aging, reaching a “frustrated” stage in the advanced aging process after 
a “fighting” state during late adulthood.   
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Conclusion: 
To sum up, we have shown that astrocytes accumulate GABA in the presence of 
amyloid depositions, in the early phase of healthy aging and as a reaction to AD-
associated mutation of PS1 in the absence of plaques. At the beginning of plaque 
formation, the initial cause for astrocytic GABA content and hypertrophy is likely 
the same, namely amyloid plaques or factors directly associated with them, for 
example oligomers that surround amyloid plaques or inflammatory factors. The 
reason for the increase in soma size might be an immune response, while 
hyperactivity of neurons may be the reason for elevated GABA levels. We 
assume that the elevated intracellular astrocytic GABA levels and GABA release 
as well as an ensuing tonic inhibition [16, 20] are defense-mechanisms of the 
brain trying to prevent neuronal hyperactivity caused by amyloid plaques or AD-
associated mutations of PS1. Therefore, it might be counterproductive to lower 
GABA levels with pharmacotherapy for AD patients, since it would impede the 
aforementioned defense mechanism and disturbances in neuronal network 
activity could possible occur at a faster rate. This approach would also prove to 
be ineffective over time, since there is a decrease in astrocytic GABA content in 
the advanced phases of the disease. A more promising way of treating AD seems 
to be the regulation of intracellular Ca2+-stores [32, 59] or inhibition of other 
mechanisms causing neuronal hyperactivity [60, 61] and therefore the prevention 
of neuronal network disturbances right when they start. 
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5. Abstract 
 
Alzheimer’s disease (AD) is the most frequent form of dementia. Mutations in the 
genes for the amyloid precursor protein (APP) or presenilin 1 (PS1) and presenilin 
2 (PS2) respectively, are mostly responsible for the onset of familiar forms of AD. 
In mouse models of AD, connections between the appearance of amyloid 
formations and disturbances of neuronal network function have been seen. 
Consequences of these disturbances are, amongst others, a change in the ratio 
of hypoactive and hyperactive neurons in the hippocampus and cortex [22, 29]. 
GABA release by reactive astrocytes in the hippocampus has been proposed as 
a balancing mechanism of the organism to counteract such neuronal 
hyperactivity [16, 20]. However, it appears that these balancing mechanisms 
have a negative effect as they lead to memory deficits.  
So far, it is unclear whether the GABA accumulation and release by astrocytes in 
the hippocampus can also be found in other areas of the brain, like the cortex, 
and how this mechanism changes during progression of the disease. 
In this study, we used immunohistochemistry to stain brain slices from AD mice 
(APP23xPS45) and age-matched wild-type (WT; C57BL/6) mice and determined 
GABA content and soma size of S100β-positive astrocytes in the cortex and 
hippocampus in three different age groups (1-2 months, 4-6 months and 9-11 
months) of both AD and WT mice. 
In the cortex, we found GABA-positive astrocytes only in the presence of amyloid 
depositions. Surprisingly, however, there was a significant decrease in astrocytic 
GABA levels as the disease progresses. In fact, GABA levels of astrocytes in 9-
11 months old AD mice were comparable to those in age-matched WT mice. This 
up-and-down trend was similarly present in the hippocampus of AD mice. 
Our data suggest that initially GABA accumulation might be caused by plaque 
deposition as we found GABA positive astrocytes only in the vicinity of plaques 
in the cortex. The reason for the decrease in astrocytic GABA content at later 
stages of the disease remains unclear [32, 41].  
We suppose that the transient increase in astrocytic GABA content is a protective 
mechanism to balance neuronal hyperactivity and hyperexcitability. This 
conclusion is supported by increased astrocytic GABA levels in PS45 and 
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normally aged mice, in which neuronal hyperactivity can also be found. This 
protective mechanism, however, only seems to be operative at the beginning of 
plaque deposition. 
This leads to the assumption that astrocytes reach two different stages over the 
course of the disease: the “fighting“ stage (high GABA levels, increased soma 
size) as a reaction to the beginning of amyloid deposition at 4-6 months and the 
“frustrated” stage (increased soma size, low GABA levels) when plaques become 
ubiquitous. 
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6. Dt. Zusammenfassung 
 
Morbus Alzheimer ist die häufigste Form der Demenz. Mutationen in den Genen 
für das Amyloid Vorläufer Protein (APP) oder Präsenilin 1 (PS1) bzw. Präsenilin 
2 (PS2) sind größtenteils für die Entstehung der familiären Form der Erkrankung 
verantwortlich. In Mausmodellen der Alzheimer-Krankheit wurde eine Verbindung 
zwischen dem Auftauchen von amyloiden Strukturen und Störungen im 
neuronalen Netzwerk entdeckt. Auswirkungen dieser Störungen sind, unter 
anderem, eine Veränderung im Verhältnis von hypoaktiven zu hyperaktiven 
Neuronen in Hippocampus und Kortex [22, 29]. Die Freisetzung von GABA aus 
reaktiven Astrozyten im Hippocampus ist potentiell eine der ausgleichenden 
Maßnahmen, um der neuronalen Hyperaktivität entgegenzuwirken [16, 20]. Es 
scheint jedoch, dass diese ausgleichenden Maßnahmen einen negativen Effekt 
mit sich bringen, da sie zu Gedächtnisverlust führen könnten. Unklar ist, ob die 
GABA Aufnahme und Freisetzung durch Astrozyten im Verlauf der Alzheimer-
Krankheit auf den Hippocampus beschränkt ist, oder ob diese Prozesse auch in 
anderen Teilen des Gehirns, beispielsweise im Kortex, stattfinden. Unklar ist 
außerdem, ob und wie sich die GABA Akkumulation in Astrozyten im Verlauf der 
Krankheit verändert. 
In dieser Studie benutzten wir Immunhistochemie in fixierten Gehirnschnitten von 
Amyloid-ablagernden Mäusen (APP23xPS45) und gleichaltrigem Wildtyp 
Mäusen (WT; C57Bl/6). Wir untersuchten die astrozytäre Somagröße, die mit 
einer Aktivierung von Astrozyten verknüpft ist, parallel zum astrozytären GABA 
Gehalt im Kortex und Hippocampus in drei verschiedenen Altersgruppen (1-2 
Monate, 4-6 Monate und 9-11 Monate). Im Kortex fanden wir GABA-positive 
Astrozyten lediglich in der Umgebung von amyloiden Ablagerungen. 
Überaschenderweise jedoch stellten wir einen signifikanten Rückgang des 
astrozytären GABA Gehalts bei fortschreitender Erkrankung fest. Tatsächlich war 
der GABA Gehalt von Amyloid-assoziierten Astrozyten aus 9-11 Monate alten AD 
Mäusen vergleichbar mit dem von gleichaltrigen WT Mäusen. Diese 
glockenförmige Entwicklung mit fortschreitender Krankheit war im Hippocampus 
von AD Mäusen ebenfalls zu beobachten. 
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Unsere Daten legen nahe, dass die GABA Aufnahme anfangs durch Plaque-
Ablagerungen verursacht werden könnte, da wir GABA positive Astrozyten nur 
im Umkreis von Plaques im Kortex und Hippocampus nachweisen konnten. Der 
Grund für den Rückgang des astrozytären GABA Gehalts in den späteren 
Phasen der Krankheit bleibt unklar [32, 41]. Wir nehmen an, dass der 
vorübergehende Zuwachs des astrozytären GABA Gehalts und die assoziierte 
GABA Freisetzung einen kompensatorischen Schutzmechanismus zum 
Ausgleich der neuronalen Hyperaktivität darstellt. Diese Vermutung wird durch 
eine Zunahme des GABA Gehalts in PS45 und normal gealterten Mäusen, bei 
denen bekannt ist, dass sie ebenfalls neuronale Hyperaktivität entwickeln, 
unterstützt.  
Dies führt zu der Annahme, dass Astrozyten im Verlauf der Krankheit zwei 
unterschiedliche Funktionszustände annehmen: einen „kämpfenden“ Zustand 
(großer GABA Gehalt, vergrößertes Soma) als Reaktion auf das Auftreten von 
amyloiden Strukturen in 4-6 Monate alten Mäusen, und einen „frustrierten“ 
Zustand (vergrößertes Soma, niedriges GABA Niveau) bei fortgeschrittener 
Amyloidose.   
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